
Parkinson's disease (PD) is a progressive neurodegenerative disorder with an increasing prevalence in the aging population. Current therapeutic approaches are largely symptomatic, and disease-modifying treatments capable of halting or slowing disease progression remain limited. This has led to growing interest in complementary and supportive strategies for the management of PD. In recent years, nutrition-related factors, particularly the gut microbiota, have attracted considerable attention due to their potential influence on the pathogenesis and clinical course of the disease. The microbiota-gut-brain axis, which describes the bidirectional communication between the gut microbiota and the central nervous system, is closely associated with key pathophysiological mechanisms of PD, including neuroinflammation, oxidative stress, and α-synuclein aggregation. Alterations in gut microbiota composition in individuals with PD have been reported to be associated with both motor and non-motor symptoms. In this context, microbiota-targeted interventions have emerged as a potential approach in disease management. Experimental and clinical studies suggest that probiotic supplementation may contribute to the improvement of gastrointestinal symptoms in patients with PD and may exert beneficial effects on certain neurological outcomes. However, evidence regarding the therapeutic efficacy of probiotics in PD remains limited, and further studies are required to clarify underlying mechanisms and strengthen clinical evidence. This narrative review aims to evaluate the therapeutic potential of probiotics in PD in light of current experimental and clinical evidence and to discuss possible mechanisms of action through the microbiota-gut-brain axis.
Modern diets are often deficient in magnesium, making magnesium supplementation an important consideration for overall human health. However, the efficiency of magnesium release and absorption in the small intestine varies among different magnesium formulations. The objective of this study was therefore to assess whether using the same magnesium salt type in different formulations could affect efficiency of magnesium release and passive diffusion in the simulated human intestine. This study utilized an in vitro simulation of the upper gastrointestinal tract under fasted conditions to evaluate capsule dissolution and levels of bioaccessible and dialyzable magnesium during transit for two magnesium bisglycinate supplements containing a similar magnesium content (Chelamax® and Albion®). For this purpose, the validated Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) technology platform was used and magnesium fractions were determined by inductively coupled plasma optical emission spectroscopy following sample extraction. Analytical validation proved that the model was fit for purpose (94-102% recovery, RSD ≤ 2.4%, R2 > 0.999, LOQ 0.04 mg/kg). Visual capsule scoring found that the Chelamax® product dissolved later in gastrointestinal transit than the Albion® product. Magnesium bioaccessibility was higher for the Chelamax® versus Albion® product in early phases of the gastrointestinal tract (i.e. duodenum), resulting in 17% higher overall Mg availability after the small intestinal incubation was complete. The level of dialyzable magnesium at the end of the small intestinal incubation was significantly higher with the Chelamax® versus Albion® product (53 mg vs. 39 mg; p = 0.0009). These results demonstrate that the Chelamax® product showed significantly higher in vitro efficiency of potentially absorbable magnesium, even upon using the same magnesium salt type, suggesting the crucial role of product formulation. Even though a proven valid in vitro methodology for the prediction of effectiveness of magnesium availability was used, future in vivo studies should confirm these findings.
This double-blind, randomized, controlled trial primarily aimed to determine how supplementation of a prenatal multivitamin with biotin levels above the Adequate Intake (AI) affected biotin status in mother-fetus dyads. Additionally, the correlation between biotin status and stress markers was also explored. Eighty healthy pregnant women were recruited between gestational week 12 and 16. They received a prenatal multivitamin containing either 150 μg (intervention) or 30 μg (control) biotin for 24 wk. Sixty-two participants completed the study. Fasting blood samples were collected at week 0, 12, and 24 and cord blood was collected at delivery to measure biotin status biomarkers and stress-related hormones. At both week 12 and 24, the intervention group had significantly higher serum biotin concentrations than the control group (p < 0.01). Cord blood biotin concentrations were also higher in the intervention than in the control group (p < 0.01). Maternal plasma concentrations of 3-hydroxyisovaleric acid-carnitine (3HIA-carnitine), a metabolite accumulated with marginal biotin insufficiency, were also more pronouncedly reduced in the intervention group (p = 0.035). Maternal stress hormone cortisol concentrations were lower (p = 0.04) in the intervention versus the control group and cortisol concentrations demonstrated a negative association with biotin concentrations in both maternal and cord blood (p < 0.05). Moreover, osteocalcin, a bone-derived hormone that suppresses chronic cortisol elevation, was positively associated with biotin concentrations in the cord blood (β = 0.013, p = 0.044). In conclusion, a higher-biotin prenatal multivitamin formulation with biotin content exceeding the AI led to increases in biotin biomarkers in the mother-fetus dyad. The higher concentrations of biotin status biomarkers were related to mitigation of stress indicators. Further research is needed to confirm the positive role of a higher biotin intake in improving maternal and fetal health. This trial was registered on ClinicalTrials.gov (NCT05673070).